PRME · Biotech · Nasdaq · As of 21 Nov 2026
Prime Medicine, Inc. stock: filings, catalysts and timeline
Sign in to follow
AIR Score
Neutral · 53 / 100
AIR confidence
Support behind the full AIR read.
What is this? →Hide
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
The Discovery Gap
High
Gap confidence
How fully AIR could measure this Gap — separate from the AIR Score's confidence.
What is this? →Hide
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Five perspectives
FundamentalsWhat is this?HideNot scored — outside AIR's $300M–$20B fundamentals band
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideToo few of the required measures on file
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideBalanced
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Rating words, not raw numbers.
Discovery Gap: High (29/100) · Gap confidence 56/100
Discovery gap
Filings show more traction than the tape reflects.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
This month at a glance
Evidence timeline
What changed — last 90 days
As of 13 Nov 2026The company disclosed preliminary Q3 2026 cash position of $61.2M excluding $13.7M restricted cash; unaudited estimates subject to completion of financial close.
Results · 8-K filed 10 Nov →
The company completed an underwritten public offering of approximately 35.7M shares at $3.50 per share, raising approximately $134.7M net proceeds.
Major contract · 8-K filed 12 Nov →
The company dosed first patient in Phase 1/2 trial of PM577a and received FDA IND clearance for PM647; raised $143.7M gross proceeds.
Results · 8-K filed 12 Nov →
The company filed its quarterly report for the period ending September 30, 2026.
Quarterly/annual report · 10-Q filed 12 Nov →
What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.
- Expected
Wed 3 Mar · expected 10-K
Last year filed 3 Mar 2026.
Fri 7 May · expected 10-Q
Last year filed 7 May 2026.
- Filed
Thu 12 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Recognition: Balanced 64 → Strong 68Gap Low · 3 → High · 29More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
Thu 12 Nov · 8-K
8-K · Item 2.02 — Results of operations
Prime Medicine dosed first patient in Phase 1/2 trial of PM577a (Wilson disease), received FDA IND clearance for PM647 (Alpha-1 Antitrypsin Deficiency), and raised $143.7M gross proceeds. BLA submission planned for PM359 in H1 2027. Cash runway extended through 2027.
Recognition: Balanced 64 → Strong 68Gap Low · 3 → High · 29More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
Thu 12 Nov · 8-K
8-K · Item 1.01 — Material agreement
Prime Medicine completed an underwritten public offering of ~35.7M shares at $3.50/share, raising ~$134.7M net proceeds. Funds will support Wilson disease and alpha-1 antitrypsin deficiency programs, R&D, and general corporate purposes.
Recognition: Balanced 64 → Strong 68Gap Low · 3 → High · 29More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
Tue 10 Nov · 8-K
8-K · Items 2.02, 8.01 — Results of operations
Prime Medicine disclosed preliminary Q3 2026 cash position of $61.2M (excluding $13.7M restricted cash) and posted updated corporate presentation. Unaudited estimates subject to completion of financial close; final results pending in 10-Q filing.
Recognition: Strong 69 → Balanced 64Market attention has faded.
The price trend weakened.
Thu 6 Aug · 8-K
Thu 6 Aug · 10-Q
Quarterly report (10-Q)
Wed 8 Jul · 8-K
Mon 8 Jun · 8-K
Thu 7 May · 8-K
Thu 7 May · 10-Q
Quarterly report (10-Q)
Thu 16 Apr · 8-K
Tue 3 Mar · 8-K
Tue 3 Mar · 10-K
Annual report (10-K)
Mon 12 Jan · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.